<div id="readability-page-1"><p>CryoPort (NASDAQ:CYRX - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.08), FiscalAI reports. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.The company had revenue of $45.45 million for the quarter, compared to analysts' expectations of $42.92 million.</p><h2>CryoPort Trading Up 3.4%</h2><p>CryoPort stock traded up $0.28 during trading hours on Tuesday, reaching $8.49. The company had a trading volume of 774,827 shares, compared to its average volume of 355,334. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. CryoPort has a 12-month low of $4.58 and a 12-month high of $11.45. The company has a 50-day moving average price of $9.54 and a 200 day moving average price of $9.41. The firm has a market cap of $425.09 million, a price-to-earnings ratio of 7.26 and a beta of 1.69. </p><h2>Insider Activity</h2><p>In related news, Director Ramkumar Mandalam sold 11,570 shares of CryoPort stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the transaction, the director directly owned 80,758 shares of the company's stock, valued at $806,772.42. The trade was a 12.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Corporate insiders own  10.10% of the company's stock. </p><h2>Hedge Funds Weigh In On CryoPort</h2><p>A number of hedge funds have recently modified their holdings of CYRX. UBS Group AG boosted its holdings in shares of  CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company's stock worth $12,623,000 after purchasing an additional 705,649 shares during the period.  Millennium Management LLC raised its position in  CryoPort by 23.8% during the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company's stock valued at $31,150,000 after purchasing an additional 623,896 shares during the last quarter.  Jacobs Levy Equity Management Inc. raised its position in  CryoPort by 283.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company's stock valued at $4,970,000 after purchasing an additional 387,440 shares during the last quarter.  Mak Capital One LLC lifted its holdings in  CryoPort by 46.6% in the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company's stock worth $11,513,000 after buying an additional 381,063 shares during the period.  Finally, Empire Financial Management Company LLC grew its position in shares of  CryoPort by 141.8% in the 4th quarter. Empire Financial Management Company LLC now owns 403,861 shares of the company's stock worth $3,877,000 after buying an additional 236,861 shares during the last quarter. Hedge funds and other institutional investors own  92.90% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>CYRX has been the topic of a number of recent research reports. Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of CryoPort in a research report on Monday, December 29th. Needham &amp; Company LLC raised their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 5th. Finally, UBS Group boosted their price target on shares of CryoPort from $11.00 to $12.50 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Eight equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat, CryoPort presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $12.83.</p><p><b>View Our Latest Stock Report on CryoPort</b></p><h2>About CryoPort</h2> (Get Free Report)<p>CryoPort, Inc <span>NASDAQ: CYRX<span></span></span> is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.  </p><p>CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.</p><h2>See Also</h2><ul><li>Five stocks we like better than CryoPort</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CryoPort Right Now?</h2><p>Before you consider CryoPort, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.</p><p>While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CYRX

<p>CryoPort (NASDAQ:CYRX) reported quarterly earnings of ($0.27) per share, missing estimates by $0.08. Despite a revenue of $45.45 million, exceeding expectations, the company had a negative return on equity of 11.07%. The stock rose 3.4% to $8.49, with a market cap of $425.09 million. Hedge funds increased their holdings, and analyst ratings show a consensus of "Moderate Buy" with a target price of $12.83. Insider activity included a director selling shares, reducing ownership by 12.53%.</p>

CryoPort (NASDAQ:CYRX) Announces Earnings Results, Misses Expectations By $0.08 EPS